Written questions by Stafford.

What assessment he has made of the potential impact of proposed mandatory alcohol labelling reforms on producers, small businesses, supply chains and exporters.

The recently published National Cancer Plan reiterated the commitment made in Fit for the Future: 10-Year Health Plan for England, to strengthen and expand on existing voluntary guidelines for alcohol labelling by introducing a mandatory requirement for alcoholic drinks to display consistent nutritional information and health warning messages.Department officials are currently exploring and assessing the potential options for and impacts of delivering this policy commitment, which includes reviewing all available and emerging evidence, and considering stakeholder feedback, having just completed a round of stakeholder engagement.The Department is working towards opening a consultation in late 2026, setting out the options under consideration, for the public and business to respond to.

Whether mandatory alcohol labelling requirements will apply to both on‑trade and off‑trade settings.

The recently published National Cancer Plan reiterated the commitment made in Fit for the Future: 10-Year Health Plan for England, to strengthen and expand on existing voluntary guidelines for alcohol labelling by introducing a mandatory requirement for alcoholic drinks to display consistent nutritional information and health warning messages.Department officials are currently exploring and assessing the potential options for and impacts of delivering this policy commitment, which includes reviewing all available and emerging evidence, and considering stakeholder feedback, having just completed a round of stakeholder engagement.The Department is working towards opening a consultation in late 2026, setting out the options under consideration, for the public and business to respond to.

What assessment her Department has made of the potential merits of mandatory alcohol health warnings for regulatory alignment with the EU, Ireland, and other trading partners.

In both the Fit for the Future: 10-Year Health Plan for England and the National Cancer Plan for England, the Government committed to strengthen and expand on existing voluntary guidelines for alcohol labelling by introducing a mandatory requirement for alcoholic drinks to display consistent nutritional information and health warning messages.Department officials have recently completed a round of stakeholder engagement regarding the policy. We are working at pace to review all available and emerging evidence.This work will inform the development assessment of policy options that will be set out in formal consultation which we are working towards opening in late 2026. International alignment will be considered as part of the process, taking into account the outcome of the Sanitary and Phytosanitary (Agri-Food) Agreement negotiations with the European Union.

To ask the Secretary of State for Health and Social Care when he plans to publish draft designs for mandatory alcohol health warnings; and what his planned timetable is for (a) consultation on and (b) the implementation of those warnings.

In Fit for the Future: 10 Year Health Plan for England, the Government committed to strengthening and expanding existing voluntary guidelines for alcohol labelling by introducing a mandatory requirement for alcoholic drinks to display consistent nutritional information and health warning messages. The plan can be accessed online at the following link:https://www.gov.uk/government/publications/10-year-health-plan-for-england-fit-for-the-futureThe Department is working towards opening a consultation in late 2026, setting out the options under consideration, for the public and businesses to respond to. The consultation will be prepared in line with guidance on seeking collective agreement across Government departments.

When the Government plans to establish a task and finish group to oversee delivery of the Life Sciences Sector Plan as it relates to generic and biosimilar medicines.

The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. As set out in the Life Sciences Sector Plan, which we developed while working closely with the sector, there is an opportunity for the National Health Service to save £1 billion over five years through biosimilars uptake, delivering value for patients and the NHS. The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.Medicines UK and its members are represented on the Single National Formulary Industry Task and Finish Group. In addition, the Government is working to convene further task and finish groups to drive forward defined areas of the Life Sciences Sector Plan, including in the generic and biosimilars space. These groups will direct focused ministerial and official attention toward a clear set of priorities and will work closely with industry to deliver tangible progress within a set timeframe.

What assessment he has made of the potential merits of reinstating the Life Sciences Council with representation from the generic and biosimilar medicines industry.

The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. As set out in the Life Sciences Sector Plan, which we developed while working closely with the sector, there is an opportunity for the National Health Service to save £1 billion over five years through biosimilars uptake, delivering value for patients and the NHS. The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.Medicines UK and its members are represented on the Single National Formulary Industry Task and Finish Group. In addition, the Government is working to convene further task and finish groups to drive forward defined areas of the Life Sciences Sector Plan, including in the generic and biosimilars space. These groups will direct focused ministerial and official attention toward a clear set of priorities and will work closely with industry to deliver tangible progress within a set timeframe.

What consideration has been given to the role of the generic and biosimilar medicines sector in shaping life sciences policy, in the context of it supplying around 85% of NHS prescription drugs by volume.

The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. As set out in the Life Sciences Sector Plan, which we developed while working closely with the sector, there is an opportunity for the National Health Service to save £1 billion over five years through biosimilars uptake, delivering value for patients and the NHS. The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.Medicines UK and its members are represented on the Single National Formulary Industry Task and Finish Group. In addition, the Government is working to convene further task and finish groups to drive forward defined areas of the Life Sciences Sector Plan, including in the generic and biosimilars space. These groups will direct focused ministerial and official attention toward a clear set of priorities and will work closely with industry to deliver tangible progress within a set timeframe.

Whether the Government plans to reinstate the Life Sciences Council.

The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. The sector is forecast to grow by £41 billion and create 100,000 jobs by 2030, supporting our ambition to lead Europe in life sciences by 2030.The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.

What steps his Department is taking to help increase the uptake of generic and biosimilar medicines to meet the objectives set out in the Government’s Life Sciences Sector Plan.

The United Kingdom is a global leader in adopting biosimilar and generic medicines, which deliver major National Health Service savings and expand patient access to effective treatments sooner. We are working with the Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence (NICE), and NHS England to understand forthcoming biosimilars and to ensure they reach the frontline efficiently. Through NHS England’s Best Value Biologicals Framework, clinicians start patients on the most cost‑effective biologics where appropriate, and switches are made swiftly and safely. This has already delivered £1.2 billion in savings over the past three years. As set out in the 10‑Year Health Plan and Life Sciences Sector Plan, we are streamlining regulation, improving procurement, and reducing variation in uptake. NICE’s whole‑lifecycle approach ensures clinical pathways are regularly reviewed so that patients benefit as soon as cost‑effective generics and biosimilars become available, as seen in recent cancer treatments. These actions support timely access to effective off‑patent medicines and a sustainable, competitive market for the NHS.

What assessment his Department has made of the potential impact of a respiratory modern service framework on winter pressures on the NHS.

Modern service frameworks will define an aspirational, long-term outcome goal for a major condition and then identify the best evidenced interventions and the support for delivery. Early priorities will include cardiovascular disease, severe mental illness, and the first ever service framework for frailty and dementia.The Government will consider other long-term conditions for future waves of modern service frameworks, including respiratory conditions. The criteria for determining other conditions for future modern service frameworks will be based on where there is potential for rapid and significant improvements in quality of care and productivity. There has not, therefore, been a specific assessment made in relation to winter pressures.NHS England, working with the Department, the UK Health Security Agency, and other partners, is taking action to reduce the impact of respiratory conditions on the National Health Service this winter. Further details of the actions being taken to reduce demand on acute services during winter is available at the following link:https://www.england.nhs.uk/long-read/urgent-and-emergency-care-plan-2025-26/

What discussions he has had with stakeholders on his Department's modelling of workforce numbers in the 10 Year Workforce Plan.

The Government will publish the 10 Year Workforce Plan in spring 2026. This plan will set out action to create a National Health Service workforce which is able to deliver the transformed service set out in the 10-Year Health Plan. It is important we do this in a robust and joined up way. We are therefore engaging extensively with partners to ensure this plan delivers for staff and patients.That engagement began well before the call for evidence was closed. In early November, ministers hosted an event with nearly one hundred representatives of partner organisations to hear views from across the health system.Engagement is now continuing while we analyse the submissions to our call for evidence, including a roundtable with medical royal colleges on 14 January, which I chaired.We have committed to publishing regular workforce planning. This will start with the 10-Year Workforce Plan, which will include updated workforce modelling and its underlying assumptions when published in spring 2026. The updated workforce modelling will be subject to independent scrutiny by our appointed external scrutiny panel.

Whether his Department plans to introduce a modern service framework for kidney disease; and what steps he is taking to support early diagnosis and prevention.

As announced in the 10-Year Health Plan, as well as an overall quality strategy, the National Quality Board is overseeing the development of a new series of service frameworks to accelerate progress in conditions where there is potential for rapid and significant improvements in quality of care and productivity.Early priorities include cardiovascular disease, severe mental illness, and the first ever service framework for frailty and dementia. The Government will consider other long-term conditions with significant health and economic impacts for future waves of modern service frameworks.NHS England is delivering a comprehensive programme to improve the diagnosis, treatment, and outcomes of people with kidney disease. In 2023, NHS England published a renal services transformation toolkit to support earlier identification of chronic kidney disease and strengthen management across the whole patient pathway.

Whether he has made an assessment of the potential merits of extending business rates reimbursements to community pharmacies.

In the 2025 Autumn Budget, the Government took the hard choices to protect the National Health Service in England and to continue to prioritise reducing waiting times. We have also stepped in to cap bills and help businesses, as part of a £4.3 billion support package.This year, we have also increased funding to community pharmacies to almost £3.1 billion, the largest uplift in funding for any part of the NHS across 2024/25 and 2025/26.The Department will consult Community Pharmacy England on any proposed changes to reimbursement and remuneration of pharmacy contractors for 2026/27 shortly.

What assessment they have made of the potential impact of abolishing local Healthwatch organisations on constituents’ ability to raise concerns about health and social care services.

The abolition of Healthwatch England and the transfer of its functions and the changes to Local Healthwatch will require primary legislation. The timing of this is subject to the will of Parliament and will happen when parliamentary time allows. A full Impact Assessment, including an Equality Impact Assessment, will be produced and published on the Government website when legislation is introduced in Parliament.We are proposing to place responsibility for the health function of local Healthwatch (LHW) with integrated care boards (ICBs). ICBs will ensure the functions are incorporated in provider organisations alongside existing patient engagement work such as Patient Participation Groups. Local authorities will be responsible for the social care LHW functions.

What progress his Department has made on developing independently verified, modelled projections of the numbers of NHS staff needed to meet future population demand in the 10-Year Workforce Plan.

The 10 Year Workforce Plan will ensure the National Health Service has the right people in the right places, with the right skills to care for patients, when they need it. It will include modelling of the potential size and shape of the future workforce and population projections.That updated workforce modelling and its underlying assumptions will be set out in and alongside the plan, when published in spring 2026. It will be supported by external independent scrutiny.

Whether his Department has made an assessment of the potential merits of increasing the accessibility of Enhertu as a treatment for breast cancer.

Decisions on whether new medicines should be routinely funded by the National Health Service in England are made on the basis of recommendations from the National Institute for Health and Care Excellence (NICE) following an evaluation of a treatment’s costs and benefits. These are very difficult decisions to make, and it is important that they are made independently and on the basis of the available evidence.NICE has recommended Enhertu (trastuzumab deruxtecan) in advanced breast cancer for treating HER2-positive unresectable or metastatic breast cancer after one or more anti-HER 2 treatments and for treating HER2-positive unresectable or metastatic breast cancer after two or more anti-HER2 therapies. Enhertu is now funded for eligible patients in England in line with NICE’s recommendations.NICE published guidance in July 2024 on the use of Enhertu for the treatment of HER-2 low metastatic and unresectable breast cancer and was unfortunately unable to recommend it for routine NHS funding. I understand that NICE and NHS England sought to apply as much flexibility as they can in their considerations of Enhertu for HER2-low breast cancer and have made it clear to the companies that their pricing of the drug remains the only obstacle to access.Ministers met with the manufacturers of Enhertu, AstraZeneca, and Daiichi Sankyo in November 2024, to encourage them to re-engage in commercial discussions with NHS England. Despite NICE and NHS England offering unprecedented flexibilities, the companies were unable to offer Enhertu at a cost-effective price. NICE’s guidance published in July 2024 will therefore remain unchanged. Although the deadline for a rapid review has now passed, NICE has reassured me that the door remains open for the companies to enter into a new NICE appraisal if they are willing to offer Enhertu at a cost-effective price.

What steps her Department is taking to increase specialist capacity for complex and rare connective tissue disorders.

We recognise the significant challenges faced by those living with complex and rare connective tissue disorders such as Ehlers-Danlos Syndrome (EDS). Optimal management of these conditions is across services beginning with primary care, including various services and pathways within primary and intermediate care, which allows for appropriate identification of those patients who have the rarer and more complex manifestations and appropriate resources for them. Integrated care boards have a statutory responsibility to commission services which meet the needs of their local population, including for those with complex and rare connective tissue disorders.A primary goal of the Complex EDS Service, which is commissioned by NHS England, is to educate referring doctors about the diagnosis, investigation, and management of patients with complex and atypical forms of EDS. While the service focuses on rare types and accepts referrals from secondary and tertiary care, its development of guidelines and educational initiatives also benefits general practitioners who are on the front line of patient care.Under the UK Rare Diseases Framework, the government is working to improve coordination of care across all rare conditions including rare connective tissue disorders.

Given the existing co-location of many health services with leisure centres, what assessment his Department has made of the benefits of including these facilities in neighbourhood health schemes.

Neighbourhood health sits at the heart of the Government’s 10-Year Health Plan. Our ambition is to build a service that: delivers more personalised care closer to where people live; empowers individuals to lead healthier, more independent lives; and offers genuine choice in how to access support. Further information on the 10-Year Health Plan is available at the following link:https://www.gov.uk/government/publications/10-year-health-plan-for-england-fit-for-the-futureWe are engaging with local government sector representatives, as well as the voluntary, community, and social enterprise sector, to understand how neighbourhood health plans and centres can make best use of the full range of existing local assets, as well as create opportunities to co-locate and join up a broad range of health-impacting services. This includes those that are local authority commissioned and owned as well as those that are National Health Service commissioned and owned.We will be publishing further guidance to support local areas to develop Neighbourhood Health Plans in due course. This will set out how the NHS, local authorities, and partners should work together under the leadership of Health and Wellbeing Boards to develop and implement plans.We expect neighbourhood teams and services to be designed in a way that reflects the specific needs of local populations. While the focus on personalised, coordinated care will be consistent, that will mean the service will look different in rural communities, coastal towns, and/or deprived inner cities.

What steps his Department is taking to include a) gyms, b) swimming pools, and c) leisure centres in the Men’s Health Strategy and 10 Year Plan.

Both the Men’s Health Strategy and the 10-Year Health Plan commit to cross sector action to reduce physical inactivity. Addressing physical inactivity and getting people moving more is important for improving health outcomes, reducing demand on the National Health Service, and supporting economic growth. The Government recognises the important role that gyms, swimming pools, and leisure centres play in providing affordable and accessible opportunities for people to increase their physical activity levels.

What steps his Department is taking to include a) gyms, b) swimming pools, and c) leisure centres in the neighbourhood health schemes.

Neighbourhood health sits at the heart of the Government’s 10-Year Health Plan. Our ambition is to build a service that: delivers more personalised care closer to where people live; empowers individuals to lead healthier, more independent lives; and offers genuine choice in how to access support. Further information on the 10-Year Health Plan is available at the following link:https://www.gov.uk/government/publications/10-year-health-plan-for-england-fit-for-the-futureWe are engaging with local government sector representatives, as well as the voluntary, community, and social enterprise sector, to understand how neighbourhood health plans and centres can make best use of the full range of existing local assets, as well as create opportunities to co-locate and join up a broad range of health-impacting services. This includes those that are local authority commissioned and owned as well as those that are National Health Service commissioned and owned.We will be publishing further guidance to support local areas to develop Neighbourhood Health Plans in due course. This will set out how the NHS, local authorities, and partners should work together under the leadership of Health and Wellbeing Boards to develop and implement plans.We expect neighbourhood teams and services to be designed in a way that reflects the specific needs of local populations. While the focus on personalised, coordinated care will be consistent, that will mean the service will look different in rural communities, coastal towns, and/or deprived inner cities.